Oppenheimer Reiterates $28.00 Price Target for Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) received a $28.00 price target from stock analysts at Oppenheimer in a research note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Oppenheimer’s target price would indicate a potential upside of 169.49% from the stock’s current price.

Several other equities research analysts also recently weighed in on the company. Zacks Investment Research raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Friday, January 5th. HC Wainwright reaffirmed a “hold” rating and issued a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Thursday, December 21st. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. Finally, Roth Capital assumed coverage on Syros Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. Syros Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $22.23.

Shares of Syros Pharmaceuticals (SYRS) traded up $0.62 during trading hours on Monday, reaching $10.39. The company’s stock had a trading volume of 242,100 shares, compared to its average volume of 241,350. The firm has a market capitalization of $280.06 and a price-to-earnings ratio of -5.97. Syros Pharmaceuticals has a 12 month low of $6.30 and a 12 month high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). research analysts forecast that Syros Pharmaceuticals will post -2.12 EPS for the current fiscal year.

In other Syros Pharmaceuticals news, Director Srinivas Akkaraju purchased 109,774 shares of Syros Pharmaceuticals stock in a transaction that occurred on Thursday, December 14th. The stock was purchased at an average price of $9.03 per share, with a total value of $991,259.22. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeremy P. Springhorn purchased 15,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. Corporate insiders own 33.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of SYRS. Schwab Charles Investment Management Inc. purchased a new position in Syros Pharmaceuticals in the second quarter valued at about $343,000. Rhumbline Advisers bought a new position in Syros Pharmaceuticals during the 2nd quarter worth approximately $198,000. Bank of New York Mellon Corp lifted its holdings in Syros Pharmaceuticals by 157.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after buying an additional 18,382 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Syros Pharmaceuticals by 360.5% during the 2nd quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock worth $366,000 after buying an additional 17,785 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in Syros Pharmaceuticals by 646.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock worth $553,000 after buying an additional 29,782 shares during the last quarter. 57.96% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Oppenheimer Reiterates $28.00 Price Target for Syros Pharmaceuticals (SYRS)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/10/oppenheimer-reiterates-28-00-price-target-for-syros-pharmaceuticals-syrs.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

What are top analysts saying about Syros Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Syros Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit